


Dantrolene-¹³C₃

Cat. No.:	HY-12542S
CAS No.:	1185234-99-4
Molecular Formula:	C ₁₁ ¹³ C ₃ H ₁₀ N ₄ O ₅
Molecular Weight:	317.23
Target:	Isotope-Labeled Compounds; Glutathione Reductase
Pathway:	Others; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Dantrolene- ¹³ C ₃ is the ¹³ C ₃ labeled Dantrolene. Dantrolene (F368), a muscle relaxant, non-competitively inhibits human erythrocyte glutathione reductase. Ki and IC50 values are 111.6 μM and 52.3 μM, respectively. Dantrolene is a ryanodine receptor antagonist and Ca ²⁺ signaling stabilizer. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome.
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. F Zhao, et al. Dantrolene inhibition of ryanodine receptor Ca²⁺ release channels. Molecular mechanism and isoform selectivity. *J Biol Chem*. 2001 Apr 27;276(17):13810-6.
- [2]. Murat Sentürk, et al. Dantrolene inhibits human erythrocyte glutathione reductase. *Biol Pharm Bull*. 2008 Nov;31(11):2036-9.
- [3]. Shigeki Kobayashi, et al. Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. *J Am Coll Cardiol*. 2009 May 26;53(21):1993-2005.
- [4]. W J Meyler, et al. The effect of dantrolene sodium on rat skeletal muscle in relation to the plasma concentration. *Eur J Pharmacol*. 1979 Feb 1;53(4):335-42.
- [5]. Xi Chen, et al. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model. *Mol Neurodegener*. 2011 Nov 25;6:81.
- [6]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019 Feb;53(2):211-216.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA